Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

It’s Time to Buy Amgen, Inc. (AMGN). Here’s Why

Page 1 of 2

Amgen, Inc. (NASDAQ:AMGN)It might not be obvious to the casual observer, but right now, today, Amgen, Inc. (NASDAQ:AMGN) stock offers one of the best values available in biotech. Why?

Three reasons.

1. Amgen is cheap
When you stack up Amgen, Inc. (NASDAQ:AMGN) against a couple of its bigger rivals — Johnson & Johnson (NYSE:JNJ) and Novartis , it’s clear that Amgen stock is the best bargain of the three. Its 16.5 price-to-earnings ratio is 10% cheaper than Novartis’s 18.3, and offers a near-28% discount to the 23 P/E at Johnson & Johnson (NYSE:JNJ).

Amgen also offers a cheaper “forward” P/E ratio — just 11.8 — and costs a mere fraction of the valuation on its rivals when measured under the rubric of price-to-free cash flow. Costing a relative pittance of just 18 times free cash, Amgen, Inc. (NASDAQ:AMGN)’s valuation is cheaper-by-half than the P/FCF ratios at either Novartis or J&J.

2. Amgen has the best record around
Over the past five years, Amgen has grown its annual profits more than twice as fast as its closest rival. Amgen’s notched a 15% annualized earnings growth to Novartis’ 6.8%, and blown Johnson & Johnson (NYSE:JNJ)’s anemic 1.2% growth rate completely out of the water.

And if Amgen, Inc. (NASDAQ:AMGN) stock looks great in the rearview mirror, it looks nearly as good when viewed through the windshield. Going forward, Amgen promises to maintain its lead. Analysts on average see the stock outgrowing J&J by nearly half, and eclipsing Novartis’s growth rate by an even larger margin.

3. Amgen pays you best
Perhaps most important to investors, though, is the fact that out of the three biotech stocks discussed above, Amgen is the firm generating the most cash from its business, giving you the biggest free cash flow bang for your investing buck.

Measured by dividing a firm’s market capitalization (the price you pay for Amgen, Inc. (NASDAQ:AMGN) stock) into its free cash flow (the money your investment generates for you), Amgen offers investors quite simply the best “free cash flow yield” of the three firms named. Put even more simply, for every $1 you invest in a share of Amgen, Inc. (NASDAQ:AMGN) stock today, you can expect the firm to generate 6.8 cents worth of real, cash profits on your investment. What’s more, Amgen has outperformed its rivals in this regard pretty consistently over time.

Page 1 of 2
Loading Comments...